Achieve Life Sciences, Inc. (ACHV) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Achieve Life Sciences, Inc. (ACHV) stock forecast summary
Our AI scores Achieve Life Sciences, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Achieve Life Sciences, Inc. is a small-cap company with a market capitalization of $692M. It ranks number 7 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast.
For ACHV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 34.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ACHV included.
ACHV price chart and AI forecast
How ACHV ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Achieve Life Sciences, Inc. (ACHV) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | ACHV | Rank |
|---|---|---|
| Market Cap | $692M | 7/17 |
| EPS | $-1.68 | – |
Profitability & Margins
| Metric | ACHV | Rank |
|---|---|---|
| ROA | -59.9% | 9/12 |
Financial Health
| Metric | ACHV | Rank |
|---|---|---|
| Current Ratio | 0.95x | 14/16 |
| Working Capital | -$9M | 15/16 |
Cash Flow
| Metric | ACHV | Rank |
|---|---|---|
| Operating Cash Flow | -$47M | 13/16 |
Income Statement
| Metric | ACHV | Rank |
|---|---|---|
| Net Income | -$114M | 9/12 |
| R&D Expense | $26M | 7/16 |
Dividend & Shareholder Information
| Metric | ACHV | Rank |
|---|---|---|
| Shares Outstanding | 103M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $188M | |
| Cash & Short-term Investments | $48M | |
| Total Liabilities | $205M |
ACHV quarterly financials and insider trading
Achieve Life Sciences, Inc. (ACHV) industry peers
Companies classified under the same SEC industry code as Achieve Life Sciences, Inc. (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ACHV Achieve Life Sciences, Inc. | $692M | |
| IDXX Idexx Laboratories Inc /De | $53.26B | |
| LNTH Lantheus Holdings, Inc. | $6.57B | |
| NEOG Neogen Corp | $2.57B | |
| CLDX Celldex Therapeutics, Inc. | $2.35B | |
| NTLA Intellia Therapeutics, Inc. | $1.59B | |
| QDEL Quidelortho Corp | $734M | |
| MYGN Myriad Genetics Inc | $566M | |
| TKNO Alpha Teknova, Inc. | $482M | |
| ICCC Immucell Corp /De/ | $90M | |
| IMDX Insight Molecular Diagnostics Inc. | $81M | |
| AWHL Aspira Women's Health Inc. | $9M | |
| BMRA Biomerica Inc | $7M | |
| CDIO Cardio Diagnostics Holdings, Inc. | $5M | |
| TRIB Trinity Biotech Plc | $5M | |
| QCLS Q/C Technologies, Inc. | $3M | |
| VNRX Volitionrx Ltd | $3M |
Where ACHV sits on the market map
Achieve Life Sciences, Inc. (ACHV) stock news
Loading...
Achieve Life Sciences, Inc. (ACHV) stock forecast FAQ
What is the Achieve Life Sciences, Inc. (ACHV) stock forecast?
Our AI scores Achieve Life Sciences, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Achieve Life Sciences, Inc. stock predictions?
For ACHV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 34.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Achieve Life Sciences, Inc. forecasts updated?
Achieve Life Sciences, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Achieve Life Sciences, Inc.'s industry peers?
17 issuers in our coverage, ACHV included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.